|
Volumn 64, Issue , 2013, Pages 329-344
|
Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole
|
Author keywords
Antibacterial; Antifungal; Benzimidazole; Chloromycin; Fluconazole; Norfloxacin
|
Indexed keywords
7 [6 [[(1H BENZO[D]IMIDAZOL 2YL)METHYL](4 FLUOROPHENYL)AMINO]HEXYLOXY] 4 METHYL 1H CHROMEN 2 ONE;
ANTIBIOTIC AGENT;
ANTIFUNGAL AGENT;
BENZIMIDAZOLE DERIVATIVE;
CHLOROMYCIN;
FLUCONAZOLE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 2 FLUOROANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 2,4 DICHLOROANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 2,4 DIFLUOROANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 3 TRIFLUOROMETHYL)ANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 3,5 BIS(TRIFLUOROMETHYL)ANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 4 CHLOROANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 4 FLUOROANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 4 IODOANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 4 METHYL N OCTADECYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 4 METHYL N OCTYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 4 METHYL N PROPYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] 4 METHYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N (2 CHLOROBENZYL) 4 METHYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N (2,4 DICHLOROBENZYL) 3 (TRIFLUOROMETHYL) ANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N (2,4 DICHLOROBENZYL) 4 FLUOROANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N (2,4 DIFLUOROBENZYL) 3,5 BIS (TRILFUOROMETHYL)ANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N (3 CHLOROBENZYL) 4 METHYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N (3,4 DICHLOROBENZYL) 2 FLUOROANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N (4 CHLOROBENZYL) 4 METHYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N DECYL 4 METHYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N DODECYL 4 METHYLANILINE;
N [(1H BENZO[D]IMIDAZOL 2 YL)METHYL)] N HEXYL 4 METHYLANILINE;
NORFLOXACIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ANTIBACTERIAL ACTIVITY;
ANTIFUNGAL ACTIVITY;
ARTICLE;
ASPERGILLUS FLAVUS;
BACILLUS SUBTILIS;
CANDIDA ALBICANS;
CARBON NUCLEAR MAGNETIC RESONANCE;
CONTROLLED STUDY;
COVALENT BOND;
DRUG EFFICACY;
DRUG POTENTIATION;
DRUG SYNTHESIS;
ESCHERICHIA COLI;
HYDROPHILICITY;
INFRARED SPECTROSCOPY;
LIPOPHILICITY;
MASS SPECTROMETRY;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;
MICROCOCCUS LUTEUS;
MINIMUM INHIBITORY CONCENTRATION;
NONHUMAN;
PROTEUS VULGARIS;
PROTON NUCLEAR MAGNETIC RESONANCE;
PSEUDOMONAS AERUGINOSA;
SACCHAROMYCES CEREVISIAE;
SALMONELLA TYPHI;
STAPHYLOCOCCUS AUREUS;
ANTI-BACTERIAL AGENTS;
ANTIFUNGAL AGENTS;
BACTERIA;
BENZIMIDAZOLES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DESIGN;
DRUG SYNERGISM;
FLUCONAZOLE;
FUNGI;
MICROBIAL SENSITIVITY TESTS;
NORFLOXACIN;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 84877021791
PISSN: 02235234
EISSN: 17683254
Source Type: Journal
DOI: 10.1016/j.ejmech.2013.03.049 Document Type: Article |
Times cited : (129)
|
References (45)
|